In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer. READ MORE

Conferences

Investigators assessed how response rate changed when patients were treated with different doses of brigatinib.

READ MORE

Investigators compared the safety and efficacy of docetaxel plus plinabulin with docetaxel alone in patients with NSCLC.

READ MORE

Using four key quality interventions in patients with non-small cell lung cancer who undergo surgery. 

READ MORE

How does stereotactic body radiation therapy affected rates of non-cancer-related deaths?

READ MORE

J Code Updates

News

In a recent study, researchers compared the efficacy of several epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of certain types of non-small cell lung cancer.

READ MORE

A recent study showed that after performing next-generation sequencing of non-small cell lung cancer gene panels, actionable mutations were identifiable in 65% of cases with available targeted therapeutic options.

READ MORE

The US Food and Drug Administration has approved the supplemental New Drug Application for alectinib as a first-line treatment for patients with a specific type of lung cancer.

READ MORE

Ethnicity, insurance status, and other factors are associated with overall survival in patients with non-small cell lung cancer.

READ MORE

Research in Review

A new prognostic model provides personalized and disease-specific predictive information for patients with non-small cell lung cancer (NSCLC) and may result in better survival outcomes.

READ MORE

A second-generation inhibitor delays anaplastic lymphoma kinase-positive lung cancer growth for a median of 15 months longer and causes fewer adverse events than the current standard of care.

READ MORE

Few patients treated with immunotherapy for metastatic non–small cell lung cancer at US community practices receive appropriate programmed death-ligand 1 expression testing.

READ MORE

Patients with non-small cell lung cancer and synchronous brain metastasis demonstrate improved 1-year and 5-year overall survival after thoracic surgery and systemic chemotherapy.

READ MORE